期刊文献+

肝素通过TLR4减少脂多糖刺激的人内皮细胞IL-8表达 被引量:3

Unfractionated heparin ameliorates lipopolysaccharide-induced expression of interleukin-8 in human endothelial cells through Toll-like receptor 4 signaling
在线阅读 下载PDF
导出
摘要 目的:观察肝素对脂多糖(lipopolysaccharide,LPS)刺激的人内皮细胞白细胞介素8(interleukin-8,IL-8)水平的影响,并探讨Toll样受体4(Toll-like receptor 4,TLR 4)在其中的可能影响。方法:用LPS(10mg/L)刺激人肺微血管内皮细胞诱导损伤,肝素治疗组提前15 min分别加入100 U/L及103U/L普通肝素,正常对照组加入等量磷酸盐缓冲液。分别在刺激2、6、12 h收集细胞上清,采用酶联免疫吸附法测定上清中IL-8的浓度。在刺激2、6、12 h收集细胞提取RNA,应用实时荧光定量聚合酶链反应检测各组细胞中IL-8、CD14及TLR4mRNA水平变化。结果:与正常对照组比较,LPS刺激组IL-8 mRNA水平增高,6 h达到高峰,其蛋白水平于12 h达到高峰。LPS刺激下TLR4 mRNA水平增高,6 h达到高峰,肝素降低其水平,差异有统计学意义(P<0.05)。未检测到CD14 mRNA的表达。结论:LPS刺激下人肺微血管内皮细胞IL-8表达增加。肝素可能通过调节TLR4降低IL-8的水平,从而发挥保护作用。 AIM:To determine the effect of unfractionated heparin(UFH) on lipopolysaccharide(LPS)-induced expression of interleukin-8(IL-8) and the role of Toll-like receptor 4(TLR4) signaling. METHODS:Human pulmonary microvascular endothelial cells(HPMECs) were either exposed to LPS alone(10 mg/L) or in combination with 100 U/L or 103 U/L UFH. UFH was added to the cells 15 min prior to stimulation with LPS. Those samples not receiving LPS or UFH received an equal volume of phosphate-buffered saline. The concentrations of IL-8 in the cell culture supernatants were detected by ELISA at 2, 6 and 12 h. The mRNA expression of IL-8, CD14 and TLR4 in HPMECs was detected by real-time fluorescence quantitative polymerase chain reaction at 2, 6 and 12 h. RESULTS:Compared with normal control group, the mRNA expression of IL-8 in LPS group was increased, and reached the peak at 6 h. The protein level of IL-8 reached the peak at 12 h. The mRNA expression of TLR4 in LPS group reached the peak at 6 h. They were down-regulated in UFH group. The mRNA expression of CD14 was not detected. CONCLUSION:The expression of IL-8 is obviously increased in LPS-treated HPMECs. UFH might exert its therapeutic effect through TLR4 signaling.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2012年第9期1699-1701,共3页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81101411)
关键词 脂多糖类 内皮细胞 肝素 受体 Toll样 白细胞介素8 Lipopolysaccharides Endothelial cells Heparin Receptors,Toll-like Interleukin-8
作者简介 通讯作者Tel:024—83282261;E—mail:xcma2972@sina.com
  • 相关文献

参考文献15

  • 1Schletter J, Heine H, Ulmer A J, et al. Molecular mecha- nisms of endotoxin activity [ J]. Arch Microbiol, 1995, 164(6) :383 - 389.
  • 2Nau GJ, Schlesinger A, Richmond JF, et al. Cumulative Toll -like receptor activation in human macrophages trea- ted with whole bacteria[J]. J lmmunol, 2003, 170( 10): 5203 - 5209.
  • 3Baggiolini M. Chemokines in pathology and medicine[ J ]. J Intern Med, 2001, 250(2) :91 - 104.
  • 4Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation [ J ]. Crit Care Med. 2001, 29 (7 Suppl) : $21 - $27.
  • 5Aird WE. Vascular bed - specific hemostasis : role of en- dothelium in sepsis pathogenesis [ J ]. Crit Care Med, 2001, 29(7 Suppl):$28-$34.
  • 6赵聪,章志丹,张晓娟,李旭,朱然,马晓春.小剂量肝素治疗脓毒症的临床分析[J].中华内科杂志,2009,48(7):566-569. 被引量:23
  • 7Takeda K, Akira S. Microbial recognition by Toll - like re- ceptors [ J ]. J Dermatol Sci, 2004, 34 (2) :73 - 82.
  • 8Haziot A, Chen S, Ferrero E, et al. The monocyte differ- entiation antigen,CDl4,is anchored to the cell membrane by a phosphatidylinositol linkage [ J ]. J Immunol, 1988, 141 (2) :547 -552.
  • 9Bazil V, Horejsi V, Baudys M, et al. Biochemical charac- terization of a soluble form of the 53 - kDa monocyte surface antigen[J]. Eur J Immunol, 1986, 16(12):1583-1589.
  • 10Malamed SF, Gagnon S, Leblanc D. Efficacy of artic- aine: a new amide local anesthetic[ J]. J Am Dent Assoc, 2000, 131(5) :635 -642.

二级参考文献15

  • 1Kinasewitz GT,Yan SB,Besson B,et al.Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis,regardless of causative micro-organism[ISBCTN74215569].Crit Care,2004,8:R82-90.
  • 2Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM Consensus Conference Committee.American College of Chest Physicians/Society of Critical Care Medicine.Chest,1992,101:1644-1655.
  • 3Bernard GR,Vincent JL,Laterre PF,et al.Efficacy and safety of recombinant human activated protein C for severe sepsis.N Engl J Med,2001,344:699-709.
  • 4Monaet X,Lamia B,Anguel N,et al.Rapid and beneficial bemodynamic effects of activated protein C in septic shock patients.Intensive Care Med,2005,31:1573-1576.
  • 5Abraham E,Laterre PF,Garg R,et al.Dretrecogin alfa (activated) for adults with severe sepsis and a low risk of death.N Engl J Meal,2005,353:1332-1341.
  • 6Schippar HG,Jenkins CS,Kahle LH,et al.Antithrombin-Ⅲ transfusion in disseminated intravaseular coagulation.Lancet,1978,1:854-856.
  • 7Fourrier F,Chopin C,Huart JJ,et al.Double-blind,placebocontrolled trial of antithrombin Ⅲ concentrates in septic shock with disseminated intravascular coagulation.Chest,1993,104:882-888.
  • 8Warren BL,Eid A,Singer P,et al.Caring for the critically ill patient.High-dose antithrombin Ⅲ in severe sepsis:a randomized controlled trial.JAMA,2001,286:1869-1878.
  • 9Wiedermann CJ,Hoffmann JN,Juers M,et al.High-dose antithrombin Ⅲ in the treatment of severe sepsis in patients with a high risk of death:efficacy and safety.Crit Care Med,2006,34:285 -292.
  • 10Abraham E,Reinhart K,Opal S,et al.Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis:a randomized controlled trial.JAMA,2003,290:238-247.

共引文献22

同被引文献16

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部